BioCentury
ARTICLE | Clinical News

Mibefradil dihydrochloride: Phase Ib started

October 20, 2014 7:00 AM UTC

Cavion said Yale University began an open-label, dose-escalation, U.S. Phase Ib trial to evaluate 150-350 mg/day oral mibefradil given over 4 daily doses with hypofractionated radiation therapy for 1...